A population-based study comparing outcomes for patients with metastatic castrate resistant prostate cancer treated by urologists or medical oncologists with first line abiraterone acetate or enzalutamide

To compare toxicity and all-cause mortality for mCRPC patients receiving first line oral systemic therapy prescribed by medical oncologists and urologists.

Source: Urology - February 12, 2021 Category: Urology & Nephrology Authors: Dixon T.S. Woon, Antonio Finelli, Douglas C. Cheung, Lisa J. Martin, Shabbir Alibhai, Christopher J.D Wallis, Christina Diong, Refik Saskin, Girish Kulkarni, Neil Fleshner Source Type: research